Approval · Notice of Compliance 28071 · 2022

JUXTAPID: Notice of Compliance 28071

Issued April 29, 2022

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 28071
Date: April 29, 2022
Company: Amryt Pharmaceuticals Dac
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: Admin
Reason: Administrative: Change in Product Ownership

Products in this notice

Brand	DIN	Status today
JUXTAPID	02420341	Marketed
JUXTAPID	02420376	Marketed
JUXTAPID	02420384	Marketed

Medicinal ingredients

LOMITAPIDE MESYLATE 5 MG per CAP
LOMITAPIDE MESYLATE 10 MG per CAP
LOMITAPIDE MESYLATE 20 MG per CAP